Pembrolizumab

August 7, 2019September 10, 2019

Keytruda Plus Chemo Increases Percentage of TNBC Patients With No Cancer Signs, Interim Analysis Shows

News

Using Keytruda (pembrolizumab) in combination with chemotherapy increased the percentage of patients showing no signs of breast cancer after completing a course of neoadjuvant therapy — treatment to shrink a ... Read more

May 24, 2019

Keytruda Fails to Improve Overall Survival of Patients with Triple-Negative Breast Cancer, Phase 3 Trial Shows

News

Keytruda (pembrolizumab), Merck‘s anti-PD-1 checkpoint blockade immunotherapy, failed to prolong the overall survival of patients with metastatic triple-negative breast cancer (TNBC) beyond that provided by chemotherapy agents, a Phase 3 ... Read more

December 3, 2018

Planned Phase 2 Trial to Test Vaccine in Triple-negative Breast Cancer Patients, Generex Says

News

Generex Biotechnology has entered into an agreement with the NSABP Foundation to manage a possible Phase 2 clinical trial testing an anti-cancer vaccine in patients with metastatic triple negative breast cancer. ... Read more

October 15, 2018

First Patient Dosed in Phase 1/2 Trial of FLX475 in Breast, Other Advanced Cancers

News

The first patient has been dosed in a Phase 1/2 trial evaluating FLX Bio’s investigational therapy, FLX475, alone and in combination with the PD-1 inhibitor Keytruda (pembrolizumab), as a therapy for triple ... Read more

June 18, 2018

Zejula-Keytruda Shows Promising Response Rates for Triple-negative Breast Cancer in Phase 1/2 Trial

News

A combination of Keytruda (pembrolizumab) and Zejula (niraparib) has shown promising and durable response rates in triple-negative breast cancer patients, regardless of their BRCA mutational status, Phase 1/2 trial data show. The trial, ... Read more

May 11, 2018

OncoSec, Merck Partner to Test Immunotherapy Combo in Phase 2 Trial for Triple-negative Breast Cancer

News

OncoSec Medical and Merck have joined efforts to conduct a Phase 2 trial evaluating the safety and effectiveness of ImmunoPulse IL-12 in combination with Keytruda (pembrolizumab) for the treatment of ... Read more

November 8, 2017

BriaVax Breast Cancer Vaccine Development Going According to Plan, Company Says

News

BriaCell Therapeutics’ Phase 1/2a study of the breast cancer vaccine BriaVax is proceeding according to plan, the company recently announced. Six patients with advanced breast cancer have received the therapeutic ... Read more

November 2, 2017November 2, 2017

‘Rollover’ Trial to Test Breast Cancer Vaccine, BriaVax, in Combo with Yervoy or Keytruda

News

A “rollover” clinical trial of BriaVax — used in combination with Keytruda (pembrolizumab) or Yervoy (ipilimumab) — will soon begin to treat women with advanced breast cancer who did not respond ... Read more

June 9, 2017September 20, 2017

Keytruda Helped Patients with Metastatic Triple-Negative Breast Cancer, Studies Find

News

Keytruda (pembrolizumab) was effective in treating triple-negative breast cancer regardless of whether women had received previous treatment, according to data presented at the 2017 American Society of Clinical Oncology (ASCO) Annual ... Read more

June 1, 2017June 1, 2017

Keytruda Shows Meaningful Clinical Benefit When Combined with Standard Therapy for Aggressive Breast Cancer

News

Two independent studies have added new evidence to the benefits of combined therapies with Merck‘s PD-1 inhibitor Keytruda (pembrolizumab) for the treatment of aggressive triple-negative breast cancer (TNBC). Adding Keytruda to standard therapies ... Read more